The week in pharma: action, reaction and insight - week to November 26

28 November 2021

By Barbara Obstoj-Cardwell

Last week’s notable news included US biotech BioMarin Pharmaceuticals receiving Food and Drug Administration approval for its Voxzogo in the treatment of achondroplasia, the most common form of dwarfism. Arrowhead Pharmaceuticals signed a heavily back-loaded agreement with the UK’s GlaxoSmithKline for its non-alcoholic steatohepatitis (NASH) candidate ARO-HSD, marking the British firm’s first foray into the sector that has seen many disappointments. Among regulatory developments, Kura Oncology had a setback last Tuesday, when the FDA put a partial clinical hold on its acute myeloid leukemia (AML) trial of KO-539 following a patient death. Finally, Ionis Pharma and partner Pfizer released Phase IIb clinical trial results for their cholesterol lowerer vupanorsen that, while meeting its primary endpoint, raised a number of questions.

BioMarin: Voxzogo launch to benefit from company experience

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK